

## Supplementary materials

**Figure S1** Study design. The native mild to moderate non-proliferative diabetic retinopathy (NPDR) subgroup included patients with mild to moderate NPDR (Diabetic Retinopathy Severity Scale [DRSS] score  $\leq 43$ ) at RIDE/RISE baseline who received sham treatment to month (M) 12. The induced mild to moderate NPDR subgroup included patients with a DRSS score up to 43 at M36 after monthly ranibizumab treatment. During the open-label extension (OLE), all patients were eligible to receive ranibizumab 0.5 mg pro re nata (PRN). DME, diabetic macular oedema.

